Key result
Dexmedetomidine sedation during PSVT ablation did not alter arrhythmia inducibility compared to fentanyl and midazolam (24% vs 26% negative electrophysiology studies; P=0.7).
Why the study?
Does dexmedetomidine sedation reduce PSVT inducibility in patients undergoing PSVT ablation?
Population
326 consecutive procedures for paroxysmal supraventricular tachycardia (PSVT) ablation
Comparison
Dexmedetomidine as the primary sedative with… vs Strictly fentanyl and midazolam used for sedation
Design
Cohort
Follow-up
intraprocedural
Authors
Loading...
Supports dexmedetomidine as sedation option for PSVT ablation; cohort data leaves open randomized confirmation.
Cohort (n=326)
Does dexmedetomidine sedation reduce PSVT inducibility in patients undergoing PSVT ablation?
Absolute Event Rate: 24% vs 26%
p-value: p=.7
Dexmedetomidine provides predictable sedation during PSVT ablation without altering arrhythmia inducibility, though it is associated with increased intraprocedural hypotension.
Slupe et al. (2018) conducted a cohort in Paroxysmal supraventricular tachycardia (PSVT) (n=326). Dexmedetomidine with adjunct fentanyl and midazolam vs. Fentanyl and midazolam was evaluated on PSVT inducibility assessed before ablation (negative EPSs) (p=.7). Dexmedetomidine sedation during PSVT ablation did not alter arrhythmia inducibility compared to fentanyl and midazolam (24% vs 26% negative electrophysiology studies; P=0.7).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: